EMEA-000574-PIP02-12-M03 - paediatric investigation plan
blinatumomab
PIPHuman
Amgen Europe B.V.
E-mail: medinfointernational@amgen.com
Tel. +44 (0)1223 420305
P/0143/2020: EMA decision of 18 April 2020 on the acceptance of a modification of an agreed paediatric investigation plan for blinatumomab (Blincyto) (EMEA-000574-PIP02-12-M03)